The Court of Appeal has overturned the High Court’s finding of non-infringement, holding Napp’s divisional patents, relating to controlled release formulations of a painkiller called oxycodone, to be valid and infringed by Ratiopharm’s and Sandoz’s ‘Cimex’ product. The Court of Appeal’s finding of infringement contrasts with decisions in Germany where the German designation of the patents were found to be not infringed.

The full summary of this case has been published on Kluwer IP Law.



Kluwer IP Law
This page as PDF